Viking Therapeutics, Inc.
US ˙ NasdaqCM ˙ US92686J1060

SecurityVKTX / Viking Therapeutics, Inc.
InstitutionIFP Advisors, Inc
Latest Disclosed Ownership60,573 shares
Latest Disclosed Value $ 1,971,045
IFP Advisors, Inc reports 1.79% decrease in ownership of VKTX / Viking Therapeutics, Inc.

On April 13, 2026 - IFP Advisors, Inc filed a 13F-HR form disclosing ownership of 60,573 shares of Viking Therapeutics, Inc. (US:VKTX) valued at $1,971,045 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 61,678 shares of Viking Therapeutics, Inc.. This represents a change in shares of -1.79% during the quarter. The current value of the position is $1,723,302 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-13 2026-03-31 13F VIKING THERAPEUTICS cs 92686J106 60,573 -1,105 -1.79 1,971 -9.13 0.0409
2026-02-06 2025-12-31 13F VIKING THERAPEUTICS cs 92686J106 61,678 1,023 1.69 2,170 36.07 0.0487
2026-02-06 2025-09-30 13F/A-1 VIKING THERAPEUTICS cs 92686J106 60,655 8,730 16.81 1,594 8.07 0.0414
2025-12-02 2025-09-30 13F VIKING THERAPEUTICS cs 92686J106 58,496 6,571 1,651 0.0426
2025-07-24 2025-06-30 13F VIKING THERAPEUTICS cs 92686J106 51,925 10,048 23.99 1,476 45.75 0.0420
2025-05-05 2025-03-31 13F VIKING THERAPEUTICS cs 92686J106 41,877 -247 -0.59 1,013 -40.37 0.0312
2025-02-04 2024-12-31 13F VIKING THERAPEUTICS cs 92686J106 42,124 21,825 107.52 1,697 32.06 0.0556
2025-02-04 2024-09-30 13F VIKING THERAPEUTICS cs 92686J106 20,299 19,769 3,730.00 1,285 4,489.29 0.0463
2024-07-30 2024-06-30 13F VIKING THERAPEUTICS cs 92686J106 530 530 28 0.0011
2023-02-07 2022-12-31 13F VIKING THERAPEUTICS cs 92686J106 0 -416 -100.00 0 -100.00
2022-11-08 2022-09-30 13F VIKING THERAPEUTICS cs 92686J106 416 0 0.00 4 0.00 0.0001
2022-09-06 2022-06-30 13F/A-1 VIKING THERAPEUTICS cs 92686J106 416 0 0.00 4 0.00 0.0001
2022-09-06 2022-03-31 13F/A-1 VIKING THERAPEUTICS cs 92686J106 416 400 2,500.00 4 300.00 0.0001
2022-08-08 2022-03-31 13F VIKING THERAPEUTICS INC COM Stock 92686J106 16 0 1 0.0000
2022-01-12 2021-12-31 13F VIKING THERAPEUTICS INC COM Stock 92686J106 16 -2,888 -99.45 1 -96.87 0.0000
2021-10-06 2021-09-30 13F VIKING THERAPEUTICS INC COM Stock 92686J106 2,904 30 1.04 32 113.33 0.0006
2021-07-13 2021-06-30 13F VIKING THERAPEUTICS INC COM Stock 92686J106 2,874 -18 -0.62 15 -6.25 0.0003
2021-04-30 2021-03-31 13F VIKING THERAPEUTICS INC COM Stock 92686J106 2,892 381 15.17 16 23.08 0.0003
2021-01-25 2020-12-31 13F VIKING THERAPEUTICS INC COM Stock 92686J106 2,511 -36 -1.41 13 -7.14 0.0005
2020-10-29 2020-09-30 13F VIKING THERAPEUTICS INC COM Stock 92686J106 2,547 0 0.00 14 -17.65 0.0008
2020-08-05 2020-06-30 13F VIKING THERAPEUTICS INC COM Stock 92686J106 2,547 0 0.00 17 41.67 0.0013
2020-05-12 2020-03-31 13F VIKING THERAPEUTICS INC COM Stock 92686J106 2,547 -635 -19.96 12 -55.56 0.0012
2020-01-17 2019-12-31 13F VIKING THERAPEUTICS INC COM Stock 92686J106 3,182 53 1.69 27 28.57 0.0020
2019-11-07 2019-09-30 13F VIKING THERAPEUTICS INC COM Stock 92686J106 3,129 2,529 421.50 21 250.00 0.0014
2019-05-15 2019-03-31 13F VIKING THERAPEUTICS Stock 92686J106 600 -2,558 -81.00 6 -75.00 0.0008
2019-06-03 2018-12-31 13F/A-10 VIKING THERAPEUTICS INC COM Stock 92686J106 3,158 2,558 426.33 24 140.00 0.0015
2019-01-23 2018-12-31 13F VIKING THERAPEUTICS INC COM Stock 92686J106 3,158 2,558 24 0.0015
2019-06-03 2018-09-30 13F/A-9 VIKING THERAPEUTICS INC COM Stock 92686J106 600 -4,000 -86.96 10 -77.27 0.0004
2018-10-25 2018-09-30 13F VIKING THERAPEUTICS INC COM Stock 92686J106 600 -4,000 10 0.0004
2019-06-03 2018-06-30 13F/A-8 VIKING THERAPEUTICS INC COM Stock 92686J106 4,600 3,725 425.71 44 1,000.00 0.0019
2018-08-07 2018-06-30 13F VIKING THERAPEUTICS INC COM Stock 92686J106 4,600 3,725 44
2018-05-09 2018-03-31 13F VIKING THERAPEUTICS INC COM Stock 92686J106 875 875 45.83 4 -33.33 0.0002
2016-08-22 2016-06-30 13F VIKING THERAPEUTICS Stock 92686J106 0 -600 -100.00 0 -100.00
2019-06-03 2016-03-31 13F/A-1 VIKING THERAPEUTICS Stock 92686J106 600 600 6 0.0008
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.